

CURRENT REPORT 4/2025

February 14, 2025

Conclusion of funding agreement with the Małopolska Centre for Entrepreneurship

The Management Board of Ryvu Therapeutics S.A., with its registered office in Kraków, Poland ("Company") informs that on February 14, 2025, a funding agreement ("Agreement") was concluded with the Małopolska Centre for Entrepreneurship ("MCP") for the Company's project titled: "InfraADC - Research infrastructure enabling R&D activities on Antibody-Drug Conjugates (ADC) as next generation targeted therapies in oncology" ("Project"). The Company informed about recommending the Project for funding in the current report 35/2024 dated November 29, 2024.

The aim of the Project is to implement new technologies, not used by the Company so far, and the required adaptation of DMPK (bioanalytical), biochemical and biological laboratories. As part of the Project, the Company plans to purchase specialist research equipment and software to control and support the operation of these devices. The acquired equipment will enable work on the technology of drug-antibody conjugates (ADC). As part of the planned R&D work, the Company plans to launch new production processes, understood as a research process for the discovery and development of innovative oncological drugs, and to expand its product portfolio with ADC projects in oncology.

- the total value of the Project is: PLN 7,523,159.70;
- recommended amount of the funding: PLN 3,085,312.00;
- assumed Project implementation period: 24 months.

The funding granted in connection with the conclusion of the Agreement will reduce the use of the Company's own funds.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Krzysztof Brzózka – Vice-President of the Management Board
- Kamil Sitarz – Member of the Management Board